Innovative Approaches to Drug Safety - Virtual Pharmacovigilance Workshop

Date & Time: 29th  January 2021 7am EST and 1pm EST

Venue: Online

Cost: Free



Introduction by Jonathan Fishbein

Implementation of Post-marketing Risk Management Commitment by Carla Perdun Barrett, PharmD

The future of pharmacovigilance with the use of artificial intelligence sounds good by Isabelle Laugel

The use of Pharmacogenomic Methodologies in the Pharmacovigilance Evaluation of Medicinal Products by Michael Marschler


Moderated discussion with speakers in a virtual hall

Glimpse into Veracuity work in the form of demo versions of products and dashboards




Veracuity was conceived out of a recognition that the practice of pharmacovigilance is performed suboptimally.  That is because it relies entirely on a voluntary reporting system – one in which consumers and healthcare professionals must devote considerable energy if they were so inclined to notify somebody about a side effect they attribute to a bio-pharmaceutical product.  Adverse event reporting is infrequent and cumbersome because stakeholders are only vaguely aware of their responsibility and the current system is neither easy nor fast to use. Nor does it provide reporters with any immediate helpful feedback.  With only a very small percentage of adverse drug events ever reaching the attention of manufacturers or regulators, it is easy to conclude that the medical community and the public may be wholly unaware of tremendous risks and liabilities that may be attributed to drug products.  



Subscribe to our newsletter